Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
IPO Year: 2021
Exchange: NASDAQ
Website: vallon-pharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/22/2021 | $12.00 | Buy | HC Wainwright & Co. |
Combined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer T ("NKT") modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseasesInvestment proceeds expected to fund planned operations of the combined company into mid-2024 Trading on Nasdaq under the ticker symbol "GRI" expected to commence April 24, 2023 PHILADELPHIA, PA, April 21, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:VLON), ("GRI," "GRI Bio," or the "Company"), today announced the completion of the previously announced merger between Vallon Pharmaceuticals, Inc. (now GRI Bio, Inc.) and GRI Bio, Inc. (now GRI Bio Operations, Inc. and referred to herein as "Priva
Vallon's board approves 1-for-30 reverse stock split Merger expected to close April 21, 2023 PHILADELPHIA, PA, April 20, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) ("Vallon" or the "Company") today announced that its stockholders have approved Proposals 1, 2, 4 and 5, related to the previously announced proposed merger with GRI Bio, Inc., a privately held biotechnology company ("GRI Bio" or "GRI"), at a special meeting of stockholders held on April 20, 2023 (the "Special Meeting"). Accordingly, at the effective time of the merger, each share of GRI's common stock, will be automatically converted into the right to receive a number of shares of Vallon's common st
Board of Directors unanimously recommend Vallon stockholders to vote "FOR" all proposals outlined in the Company's definitive Proxy Statement (the "Proxy") in order to close the proposed merger with GRI Bio, Inc. PHILADELPHIA, PA, April 12, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), today announced that its Special Meeting of Stockholders, scheduled for and convened on April 12, 2023, has been adjourned to provide the Company's stockholders additional time to consider and vote FOR the proposals in the Proxy. Vallon intends to reconvene the Special Meeting on April 20, 2023 at 9:00 am ET. The Vallon board of directors unanimou
Over 90% of the shares voted to date have shown support "FOR" each of the five proposals, but additional votes are needed in order to close the proposed merger with GRI Bio PHILADELPHIA, PA, April 04, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), today urges its stockholders of record as of March 6, 2023 to vote in favor of all of the proposals outlined in the Company's definitive Proxy Statement (the "Proxy") for the upcoming Special Stockholder Meeting to be held virtually at 9:00 AM ET on April 12, 2023. The proposals outlined in the Proxy include the proposed Merger with GRI Bio, Inc. The Merger will result in a clinical
PHILADELPHIA, PA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), today reported its financial results for the fiscal year ended December 31, 2022. In December 2022, Vallon announced it had entered into a definitive agreement (the "Merger Agreement") with GRI Bio, Inc. ("GRI Bio"), a privately held biotechnology company with the goal of advancing an innovative pipeline of Natural Killer T ("NKT") cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases. Pursuant to the Merger Agreement, GRI Bio will merge with a wholly-owned subsidiary of Vallon in an all-stock transaction (the "Merger"). The combine
- Live video webcast presentations with participating companies -FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023. As part of the virtual event, participating companies will provide a corporate presentation.The schedule for the event is as follows:Tuesday, January 17, 20239:00 AM ET: Moleculin Biotech, Inc. (NASDAQ:MBRX) - WEBCAST10:00 AM ET: Xenetic Biosciences, Inc. (NASDAQ:XBIO) - WEBCAST11:00 AM ET: Outlook Therapeutics, Inc. (NASDAQ:OTLK) - WEBCAST1:00 PM ET: Vallon Pharmaceuticals, Inc. (NASDAQ:VL
Live video webcast on Tuesday, January 17, 2023 at 1:00 PM ET PHILADELPHIA, PA and LA JOLLA, CA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), and GRI Bio, Inc. ("GRI Bio"), a privately held biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that David Baker, President & Chief Executive Officer of Vallon and Marc Hertz, Chief Executive Officer of GRI Bio, will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 1:00 PM ET. As part of the presentation, Vall
Combined company will operate as GRI Bio and advance innovative pipeline of Natural Killer T (NKT) regulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases GRI Bio has committed capital to fund planned operations of the combined company into mid-2024 Companies to hold a joint webcast on December 14, 2022 at 8:30 AM ET PHILADELPHIA, PA and LA JOLLA, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), and GRI Bio, Inc. ("GRI Bio"), a privately held biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell regulators for the treatment of inflammatory, fib
PHILADELPHIA, PA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended September 30, 2022. David Baker, Chief Executive Officer of Vallon, commented, "Our process for exploring strategic alternatives remains active and ongoing. We plan to provide an update upon the completion of our evaluation of potential opportunities." In April 2022, the Company engaged Ladenburg Thalmann & Co. Inc. for
PHILADELPHIA, PA, July 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended June 30, 2022 and provided a corporate update. Second Quarter 2022 Highlights Engaged Ladenburg Thalmann & Co. Inc. for an evaluation of strategic alternatives for the Company. The review of strategic alternatives remains ongoing and could include, without limitation, exploring the potential for a possible merger, bus
4 - GRI BIO, Inc. (0001824293) (Issuer)
4 - GRI BIO, Inc. (0001824293) (Issuer)
4 - GRI BIO, Inc. (0001824293) (Issuer)
4 - GRI BIO, Inc. (0001824293) (Issuer)
4 - GRI BIO, Inc. (0001824293) (Issuer)
3 - GRI BIO, Inc. (0001824293) (Issuer)
3 - GRI BIO, Inc. (0001824293) (Issuer)
3 - GRI BIO, Inc. (0001824293) (Issuer)
3 - GRI BIO, Inc. (0001824293) (Issuer)
3 - GRI BIO, Inc. (0001824293) (Issuer)
HC Wainwright & Co. initiated coverage of Vallon Pharmaceuticals with a rating of Buy and set a new price target of $12.00
424B3 - GRI BIO, Inc. (0001824293) (Filer)
8-K - GRI BIO, Inc. (0001824293) (Filer)
424B4 - GRI BIO, Inc. (0001824293) (Filer)
EFFECT - GRI BIO, Inc. (0001824293) (Filer)
S-1/A - GRI BIO, Inc. (0001824293) (Filer)
S-1/A - GRI BIO, Inc. (0001824293) (Filer)
424B3 - GRI BIO, Inc. (0001824293) (Filer)
8-K - GRI BIO, Inc. (0001824293) (Filer)
424B3 - GRI BIO, Inc. (0001824293) (Filer)
8-K - GRI BIO, Inc. (0001824293) (Filer)
SC 13G - GRI BIO, Inc. (0001824293) (Subject)
SC 13G - GRI BIO, Inc. (0001824293) (Subject)
SC 13D - GRI BIO, Inc. (0001824293) (Subject)
SC 13D - GRI BIO, Inc. (0001824293) (Subject)
SC 13D - GRI BIO, Inc. (0001824293) (Subject)
SC 13G/A - Vallon Pharmaceuticals, Inc. (0001824293) (Subject)
SC 13G/A - Vallon Pharmaceuticals, Inc. (0001824293) (Subject)
SC 13G/A - Vallon Pharmaceuticals, Inc. (0001824293) (Subject)
SC 13G - Vallon Pharmaceuticals, Inc. (0001824293) (Subject)
SC 13G - Vallon Pharmaceuticals, Inc. (0001824293) (Subject)
Global biopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and capital markets experience spanning both private and public large pharma and small biotech companies Philadelphia, PA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the appointment of Meenu Karson to its Board of Directors. "We are excited to welcome Ms. Karson to our Board of Directors. Over the course of her career, she has l
- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall® segment of the ~$9 billion US ADHD market PHILADELPHIA, PA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended June 30, 2021. The Company also provided an update on its development programs, ADAIR and ADMIR
- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm PHILADELPHIA, PA, May 11, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the appointment of Leanne Kelly as its Chief Financial Officer. Ms. Kelly is an accomplished financial executive with over 20 years of experience leading private and publicly traded companies across life science, technology and e